United Therapeutics (UTHR) Other financing activities (2009 - 2025)

United Therapeutics has disclosed Other financing activities across 16 years of filings, most recently posting $11.5 million for Q2 2025.

• Other financing activities for Q2 2025 came in at $11.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $11.5 million (up 325.93% YoY), and the FY2025 annual result was $11.5 million, up 325.93% from the prior year.
• Other financing activities came in at $11.5 million for Q2 2025 at United Therapeutics, up from $2.7 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $11.5 million in Q2 2025 to a low of $2.7 million in Q1 2023.
• The 4-year median for Other financing activities is $5.1 million (2022), against an average of $6.1 million.
• Across the five-year window, Other financing activities tumbled 64.0% in 2023 and changed 0.0% in 2024, its largest moves.
• United Therapeutics' Other financing activities stood at $7.5 million in 2022, then sank by 64.0% to $2.7 million in 2023, then changed by 0.0% to $2.7 million in 2024, then jumped by 325.93% to $11.5 million in 2025.
• The last three Other financing activities figures came in at $11.5 million (Q2 2025), $2.7 million (Q1 2024), and $2.7 million (Q1 2023), per Business Quant data.